⌕
ADMA Biologics · ADMA · Nasdaq
Tenet 72 · Solid
Compare
$13.47−1.54%At closeTenet 72 · Solid
$13.47−0.21 (−1.54%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

ADMA Biologics (ADMA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 13, 2026 · 10:51 ET
Here's Why Adma Biologics (ADMA) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

● Zacks Investment ResearchNov 11, 2026 · 17:21 ET
Why Adma Biologics (ADMA) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.…

● Zacks Investment ResearchNov 11, 2026 · 13:46 ET
ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?

ADMA Biologics gains 20.9% after strong Q3 results, as surging Asceniv sales and a raised 2026 profit outlook offset Bivigam weakness and competitive pressures.…

● Zacks Investment ResearchNov 6, 2026 · 10:36 ET
Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average

After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.…

● Zacks Investment ResearchNov 6, 2026 · 10:31 ET
Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average

From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 200-day moving average, and this suggests a long-term bullish…

● Seeking AlphaNov 5, 2026 · 00:06 ET
ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript

ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 4, 2026 · 20:51 ET
Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates

Adma Biologics (ADMA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.…

● MarketBeatNov 4, 2026 · 18:15 ET
ADMA Biologics Q3 Earnings Call Highlights

ADMA Biologics NASDAQ: ADMA raised its minimum full-year earnings expectations after third-quarter profit rose on stronger sales of ASCENIV and improved manufacturing yields, even as competitive pressure weighed on its B…

● GlobeNewsWireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDS
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year  3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year 3Q 2…

● Zacks Investment ResearchOct 30, 2026 · 18:46 ET
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $11.41, denoting a -2.89% move from the preceding trading day.…

● Zacks Investment ResearchOct 29, 2026 · 10:31 ET
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's …

● Zacks Investment ResearchOct 29, 2026 · 10:01 ET
Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know

Adma Biologics (ADMA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.…

● GlobeNewsWireOct 28, 2026 · 07:00 ETCOMPANY'S OWN WORDS
ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

RAMSEY, N.J. and BOCA RATON, Fla.…

● Zacks Investment ResearchOct 20, 2026 · 18:51 ET
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing

Adma Biologics (ADMA) closed the most recent trading day at $11.24, moving +1.49% from the previous trading session.…

● GlobeNewsWireOct 15, 2026 · 07:00 ETCOMPANY'S OWN WORDS
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield…

● Zacks Investment ResearchOct 12, 2026 · 10:31 ET
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) ana…

● Defense WorldOct 12, 2026 · 01:28 ET
ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical Analysis

Myriad Genetics (NASDAQ: MYGN - Get Free Report) and ADMA Biologics (NASDAQ: ADMA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the streng…

● Zacks Investment ResearchOct 8, 2026 · 18:51 ET
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors

In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.…

● Zacks Investment ResearchOct 8, 2026 · 10:00 ET
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.…

● Defense WorldOct 5, 2026 · 04:28 ET
ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of ADMA Biologics Inc (NASDAQ: ADMA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Three investment analy…

● Zacks Investment ResearchSep 29, 2026 · 18:46 ET
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.…

● Zacks Investment ResearchSep 24, 2026 · 18:51 ET
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today

Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.…

● Zacks Investment ResearchSep 24, 2026 · 10:30 ET
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) ana…

● Zacks Investment ResearchSep 18, 2026 · 18:50 ET
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.…

● Newsfile CorpSep 14, 2026 · 09:21 ET
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)

Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA …

● PRNewsWireSep 8, 2026 · 09:09 ET
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ:…

● PRNewsWireAug 31, 2026 · 14:35 ET
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ:…

● Newsfile CorpAug 26, 2026 · 09:26 ET
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain direct…

● Newsfile CorpAug 24, 2026 · 12:06 ET
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)

Philadelphia, Pennsylvania--(Newsfile Corp. - August 24, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Bio…

● PRNewsWireAug 21, 2026 · 04:38 ET
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Se…

● PRNewsWireAug 21, 2026 · 04:38 ET
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Com…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just ADMA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.